Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder

American Journal of Psychiatry

Volumn 161, Issue 11, 2004, Pages 2060-2065

  Birkenhäger, Tom K ^a   Van Den Broek, Walter W ^b   Mulder, Paul G ^b   Bruijn, Jan A ^b   Moleman, Peter ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; LORAZEPAM; VALERIAN;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HOSPITALIZATION; HUMANS; IMIPRAMINE; LITHIUM; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 7444238101     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.11.2060     Document Type: Article

References (26)

1. Bauer M, Döpfmer S: Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19:427-434
2. Austin MP V, Souza FG, Goodwin GM: Lithium augmentation in antidepressant-resistant patients: a quantitative analysis. Br J Psychiatry 1991; 159:510-514
3. Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, Burns RA, Robertson MM: Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166:80-86
4. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Perey M: A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16:307-314
5. Hoencamp E, Haffmans PM, Dijken WA, Huijbrechts IPAM: Lithium augmentation of venlafaxine: an open-label trial. J Clin Psychopharmacol 2000; 20:538-543
6. de Montigny C, Grunberg F, Mayer A, Deschenes JP: Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138:252-256
7. Stein G, Bernadt M: Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162:634-640
8. Bruijn JA, Moleman P, Mulder PGM, van den Broek WW: Comparison of 2 treatment strategies for depressed in patients: imipramine and lithium addition or mirtazapine and lithium addition. J Clin Psychiatry 1998; 59:657-663
9. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E: Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996; 153:414-416
10. van den Broek WW, Birkenhäger TK, Mulder PG, Bruijn JA, Moleman P: A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology (Berl) 2004; Jul 8 (e-pub ahead of print)
11. Spitzer RL, Endicott J: Schedule for Affective Disorders and Schizophrenia - Lifetime Version, 3rd ed. New York, New York State Psychiatric Institute, Biometrics Research, 1979
12. Pullen RH, Fatmi AA: Determination of fluvoxamine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1992; 574:101-107
13. Foglia JP, Perel JM, Nathan RS, Pollock BG: Therapeutic drug monitoring of fluvoxamine, a selective antidepressant (abstract). Clin Chem 1990; 36:1043
14. De Wilde JE, Mertens C, Wakelin JS: Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. Br J Clin Pharmacol 1983; 15(suppl 3):427S-431S
15. Klok CJ, Brouwer GJ, van Praag HM, Doogan D: Fluvoxamine and clomipramine in depressed patients: a double-blind clinical study. Acta Psychiatr Scand 1981; 64:1-11
16. Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S: The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 1990; 10:96-104
17. Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, Greenberg R, Rifas SL, Sackeim HA: Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996; 153:985-992
18. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Revision). Am J Psychiatry 2000; 157(April suppl)
19. Schatzberg AF, Rothschild AJ: Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992; 149:733-745
20. Bruijn JA, Moleman P, Mulder PG, van den Broek WW: Treatment of mood-congruent psychotic depression with imipramine. J Affect Disord 2001; 66:165-174
21. Maj M, Pirozzi R, DiCaprio EL: Major depression with mood-congruent psychotic features: a distinct diagnostic entity or a more severe subtype of depression? Acta Psychiatr Scand 1990; 82:439-444
22. Paykel ES: Remission and residual symptomatology in major depression. Psychopathology 1998; 31:5-14
23. Scott J: Chronic depression. Br J Psychiatry 1988; 153:287-297
24. Öhman R, Spigset O: Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry 1993; 26:263-264
25. Perry PJ, Pfohl BM, Holstad SG: The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet 1987; 13:381-391
26. Bauer M, Whybrow PC, Angst J, Versiani M, Möller H-J: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3:5-43